RxDoctor Payments DataLook up a doctor →

Max Rabinowitz, MD

Hematology & Oncology · Anchorage, AKNPI 1295770972

Payments from drug & device makers

$13,912in general payments, 2019–2025

Across 649 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Johnson & Johnson$986
  • Novartis$772
  • E.r. Squibb & Sons, L.L.C.$608
  • Pfizer$562
  • Astellas Pharma US Inc$545
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$13,59998%
  • Education$3132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)68$1,444
Johnson & Johnson(2 entities)49$986
Novartis45$772
E.r. Squibb & Sons, L.L.C.31$608
Pfizer34$562
Astellas Pharma US Inc19$545
Bristol Myers Squibb21$473
AbbVie17$415
Genentech USA, Inc.21$400
Amgen15$346
Pharmacyclics LLC, An Abbvie Company17$336
Incyte Corporation16$312
GSK14$304
Regeneron Healthcare Solutions, Inc.9$276
Seagen Inc.16$276
Merck12$271
Bayer13$265
Daiichi Sankyo Inc.8$259
EMD Serono, Inc.12$253
Boehringer Ingelheim10$217
Sanofi8$212
Stemline Therapeutics Inc.6$193
Array Biopharma Inc10$188
Exelixis Inc.6$167
Blueprint Medicines Corporation7$164
Coherus Oncology, Inc.7$159
Clovis Oncology, Inc.9$151
Eisai Inc.7$144
Takeda Pharmaceuticals U.S.A., Inc.6$141
Sobi, Inc6$135
Rigel Pharmaceuticals, Inc.5$131
Genmab U.S., Inc.4$118
Lilly USA, LLC6$116
Gilead(2 entities)5$115
Apellis Pharmaceuticals, Inc.4$111
Servier Pharmaceuticals LLC5$100
Acrotech Biopharma Inc.5$98
Intuitive Surgical3$96
Taiho Oncology, Inc.4$95
Tersera Therapeutics LLC3$95
Beigene USA, Inc.4$94
Puma Biotechnology, Inc.4$92
Chiesi USA, Inc.4$91
AVEO Pharmaceuticals, Inc.5$91
Ipsen Biopharmaceuticals, Inc4$90
Spectrum Pharmaceuticals Inc.4$84
Adaptive Biotechnologies Corporation4$84
Jazz Pharmaceuticals Inc.4$75
Springworks Therapeutics, Inc.3$72
Mirati Therapeutics, Inc.3$71
Deciphera Pharmaceuticals Inc.3$65
Geron Corporation3$61
ADC Therapeutics America, Inc.2$46
Sanofi-aventis U.S. LLC2$45
Pharmacosmos Therapeutics Inc.2$44
Tempus AI, Inc2$43
Alnylam Pharmaceuticals Inc.2$40
Dova Pharmaceuticals2$39
Sun Pharmaceutical Industries Inc.2$38
Helsinn Therapeutics (U.S.), Inc.2$36

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$5,721,638
Medicare patients
544
Services billed
171,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide48$855,864
Lenalidomide49$623,501
TagrissoOsimertinib Mesylate32$576,027
ImbruvicaIbrutinib34$479,820
AyvakitAvapritinib11$462,095
PomalystPomalidomide17$431,205
InlytaAxitinib19$380,688
RevlimidLenalidomide14$312,765
LenvimaLenvatinib Mesylate11$265,010
NubeqaDarolutamide19$258,750
CalquenceAcalabrutinib Maleate13$234,174
JakafiRuxolitinib Phosphate13$228,369
EliquisApixaban51$53,323
XareltoRivaroxaban27$24,520
Janumet XrSitagliptin Phos/Metformin Hcl11$6,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$986$880,38475 claims
AstraZenecaTagrisso, Calquence$1,444$810,20145 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$336$479,82034 claims
Blueprint Medicines CorporationAyvakit$164$462,09511 claims
PfizerInlyta, Eliquis$562$434,01170 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$608$431,20517 claims
Bristol Myers SquibbRevlimid$473$312,76514 claims
Eisai Inc.Lenvima$144$265,01011 claims
BayerNubeqa$265$258,75019 claims
Incyte CorporationJakafi$312$228,36913 claims
MerckJanumet Xr$271$6,15411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →